Camós Mireia, Esteve Jordi, Jares Pedro, Colomer Dolors, Rozman María, Villamor Neus, Costa Dolors, Carrió Ana, Nomdedéu Josep, Montserrat Emili, Campo Elías
Hematopathology Unit, Hematology Department, Hospital Clínic, IDIBAPS, University of Barcelona, Spain.
Cancer Res. 2006 Jul 15;66(14):6947-54. doi: 10.1158/0008-5472.CAN-05-4601.
Acute myeloid leukemia (AML) with translocation t(8;16)(p11;p13) is an infrequent leukemia subtype with characteristic clinicobiological features. This translocation leads to fusion of MYST3 (MOZ) and CREBBP (CBP) genes, probably resulting in a disturbed transcriptional program of a myelomonocytic precursor. Nonetheless, its gene expression profile is unknown. We have analyzed the gene expression profile of 23 AML patients, including three with molecularly confirmed MYST3-CREBBP fusion gene, using oligonucleotide U133A arrays (Affymetrix). MYST3-CREBBP cases clustered together and clearly differentiated from samples with PML-RARalpha, RUNX1-RUNX1T1, and CBFbeta-MYH11 rearrangements. The relative expression of 46 genes, selected according to their differential expression in the high-density array study, was analyzed by low-density arrays in an additional series of 40 patients, which included 7 MYST3-CREBBP AML cases. Thus, genes such as prolactin (PRL) and proto-oncogene RET were confirmed to be specifically overexpressed in MYST3-CREBBP samples whereas genes such as CCND2, STAT5A, and STAT5B were differentially underexpressed in this AML category. Interestingly, MYST3-CREBBP AML exhibited a characteristic pattern of HOX expression, with up-regulation of HOXA9, HOXA10, and cofactor MEIS1 and marked down-regulation of other homeobox genes. This profile, with overexpression of FLT3, HOXA9, MEIS1, AKR7A2, CHD3, and APBA2, partially resembles that of AML with MLL rearrangement. In summary, this study shows the distinctive gene expression profile of MYST3-CREBBP AML, with overexpression of RET and PRL and a specific pattern of HOX gene expression.
伴有t(8;16)(p11;p13)易位的急性髓系白血病(AML)是一种罕见的白血病亚型,具有独特的临床生物学特征。这种易位导致MYST3(MOZ)和CREBBP(CBP)基因融合,可能导致骨髓单核细胞前体的转录程序紊乱。尽管如此,其基因表达谱仍不清楚。我们使用寡核苷酸U133A芯片(Affymetrix)分析了23例AML患者的基因表达谱,其中包括3例经分子确认有MYST3-CREBBP融合基因的患者。MYST3-CREBBP病例聚集在一起,与伴有PML-RARalpha、RUNX1-RUNX1T1和CBFbeta-MYH11重排的样本明显区分开来。根据在高密度芯片研究中的差异表达选择的46个基因的相对表达,在另外40例患者的系列研究中通过低密度芯片进行分析,其中包括7例MYST3-CREBBP AML病例。因此,催乳素(PRL)和原癌基因RET等基因在MYST3-CREBBP样本中被证实特异性过表达,而CCND2、STAT5A和STAT5B等基因在该AML类别中差异低表达。有趣的是,MYST3-CREBBP AML表现出特征性的HOX表达模式,HOXA9、HOXA10和辅助因子MEIS1上调,其他同源框基因明显下调。这种伴有FLT3、HOXA9、MEIS1、AKR7A2、CHD3和APBA2过表达的表达谱,部分类似于伴有MLL重排的AML。总之,本研究显示了MYST3-CREBBP AML独特的基因表达谱,RET和PRL过表达以及HOX基因表达的特定模式。